Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock

Journal of Pediatric Gastroenterology and Nutrition

Volumn 55, Issue 4, 2012, Pages 403-407

  Chu, Hui Ping ^a   Brind, Joanne ^a   Tomar, Rajeev ^a   Hill, Susan ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Bloodstream infection; Central venous catheter; Home parenteral nutrition; Taurolidine

Indexed keywords

HEPARIN; TAUROLIDINE;

CATHETER INFECTION; CENTRAL VENOUS CATHETER; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENTEROPATHY; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; LONG TERM CARE; MEDICAL RECORD REVIEW; PARENTERAL NUTRITION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SHORT BOWEL SYNDROME;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CENTRAL VENOUS CATHETERS; CHILD; CHILD, PRESCHOOL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; PARENTERAL NUTRITION, HOME; SEPSIS; SHORT BOWEL SYNDROME; TAURINE; THIADIAZINES; YOUNG ADULT;

EID: 84867023169     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31825bb0ae     Document Type: Review

References (30)

1. Beath SV, Gowen H, Puntis JW. Trends in paediatric home parenteral nutrition and implications for service development. Clin Nutr 2011;30:499-502.
2. Emedo M, Godfrey EI, Hill SM. A qualitative study of the quality of life of children receiving intravenous nutrition at home. J Paediatr Gastroenterol Nutr 2010;50:431-40.
3. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002;23:759-69. (Pubitemid 36020215)
4. Candusso M, Faraguna D, Sperli D, et al. Outcome and quality of life in paediatric home parenteral nutrition. Curr Opin Clin Nutr Metab Care 2005;5:309-14.
5. Brind J. Retaining central venous catheters in paediatric parenteral nutrition. Nurs Stand 2009;23(52):43-38.
6. Hall K, Farr B. Diagnosis and management of long-term central venous catheter infections. J Vasc Interv Radiol 2004;15:327-34. (Pubitemid 38451975)
7. Berenholtz S, Pronovost PJ, Lipsett PA, et al. Eliminating catheterrelated bloodstream infections in the intensive care unit. Crit Care Med 2004;32:2014-20. (Pubitemid 39372534)
8. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-22. (Pubitemid 29289651)
9. Bisseling TM, Willems MC, Versleijen MW, et al. Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial. Clin Nutr 2010;29:464-8.
10. Walshe CM, Boner KS, Bourke J, et al. Diagnosis of catheter-related bloodstream infection in a total parenteral nutrition population: inclusion of sepsis defervescence after removal of culture-positive central venous catheter. J Hosp Infect 2010;76:119-23.
11. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8. (Pubitemid 32709857)
12. Jones BA, Hull MA, Richardson DS, et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J Pediatr Surg 2010;45:1287-93.
13. Gorman SP, McCafferty DF, Woolfson AS, et al. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with taurolin, a novel anti-microbial agent. J Appl Bacteriol 1987; 62:315-20.
14. Allon M. Prophylaxis against dialysis catheter-related bacteraemia with a novel antimicrobial lock solution. Clin Infect Dis 2003;36:1539-44. (Pubitemid 36783336)
15. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000;44:1720-4. (Pubitemid 30340825)
16. Bradshaw JH, Puntis JWL. Taurolidine and catheter related bloodstream infection: a systematic review of the literature. J Pediatr Gastroenterol Nutr 2008;47:179-86.
17. Centers for Disease Control and Prevention. Guidelines on central line associated bloodstream infections (CLABSI) event. www.cdc.gov/nhsn/PDFs/ pscManual/4PSC-CLABScurrent.pdf. Accessed August 17, 2012.
18. Browne MK. The treatment of peritonitis by an antiseptic - taurolin. Pharmatherapeutica 1981;2:517-22.
19. Conlan AA, Abramor E, Delikaris P, et al. Taurolidine instillation as therapy for empyema thoracis. A prospective study of 50 patients. S Afr Med J 1983;64:653-5. (Pubitemid 14235528)
20. Solomon LR, Cheesbrough JS, Ebah L, et al. A randomized doubleblind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis 2010;55:1060-8.
21. Taylor C, Cahill J, Gerrish M, et al. A new haemodialysis catheterlocking agent reduces infections in haemodialysis patients. J Ren Care 2008;34:116-20.
22. Simon A, Ammann RA, Wiszniewsky G, et al. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis 2008;8:102.
23. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2004;24:491-5. (Pubitemid 39425163)
24. Blenkharn JI. The antimicrobial activity of taurolin - a possible additive for parenteral nutrition solutions. Clin Nutr 1987;6:35-8. (Pubitemid 17030253)
25. Johnston DA, Phillips G, Perry M, et al. Taurolin for the prevention of parenteral nutrition related infection: antimicrobial activity and longterm use. Clin Nutr 1993;12:365-8. (Pubitemid 24006134)
26. Jurewitsch B, Lee T, Park J, et al. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infection. J Parenter Enteral Nutr 1998;22:242-4. (Pubitemid 28307589)
27. Jurewitsch B, Jeejeebhoy KN. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. Clin Nutr 2005; 24:462-5. (Pubitemid 40668434)
28. Tacconelli E, Smith G, Hieke K, et al. Epidemiology, medical outcomes and costs of cathter related bloodstreaminfections in intensive care units of four European countries: literatureand registry-based estimates. J Hosp Infect 2009;72:97-103.
29. Jacobi CA, Menenakos C, Braumann C. Taurolidine - a new drug with anti-tumor and antiangiogenic effects. Anticancer Drugs 2005;16:917-21. (Pubitemid 41416082)
30. Reinmuller J. The influence of taurolidine on physiological and pathological coagulation and implications for its use. Zentralbl Chir 1999;124 (suppl 4):13-8. (Pubitemid 30119557)